Article
Pharmacology & Pharmacy
F. Markus Leweke, Cathrin Rohleder, Christoph W. Gerth, Martin Hellmich, Ralf Pukrop, Dagmar Koethe
Summary: CBD and AMI show comparable efficacy in improving neurocognitive functioning in young and acutely ill schizophrenia patients, with CBD also enhancing sustained attention and visuomotor coordination.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Medicine, General & Internal
Ming-Huan Zhu, Zhen-Jing Liu, Qiong-Yue Hu, Jia-Yu Yang, Ying Jin, Na Zhu, Ying Huang, Dian-Hong Shi, Min-Jia Liu, Hong-Yang Tan, Lei Zhao, Qin-Yu Lv, Zheng-Hui Yi, Feng-Chun Wu, Ze-Zhi Li
Summary: This study aimed to investigate the efficacy of amisulpride augmentation therapy in treating patients with treatment-resistant schizophrenia. The results showed that amisulpride augmentation therapy improved psychiatric symptoms and cognitive function with tolerability and safety.
MILITARY MEDICAL RESEARCH
(2022)
Article
Psychiatry
Mengling Deng, Zhi Yang, Yanfei Ni, Lingli Zhu, Jiating Xu, Lifeng Zheng, Bo Zhou
Summary: This study investigated the impact of smoking cessation with varenicline on the serum concentration of olanzapine in patients with Schizophrenia. The results indicated that olanzapine concentrations increased nonlinearly in both the varenicline and placebo groups over the 12-week study period, but there was no significant difference between the two treatment groups.
FRONTIERS IN PSYCHIATRY
(2023)
Article
Psychiatry
Stephan Heres, Joachim Cordes, Sandra Feyerabend, Christian Schmidt-Kraepelin, Richard Musil, Michael Riedel, Ilja Spellmann, Berthold Langguth, Michael Landgrebe, Elmar Fran, Camelia C. Petcu, Eric Hahn, Tam M. T. Ta, Valentin Matei, Liana Dehelean, Ion Papava, F. Markus Leweke, Till van der List, Simona C. Tamasan, Fabian U. Lang, Dieter Naber, Stephan Ruhrmann, Claus Wolff-Menzler, Georg Juckel, Maria Ladea, Cristinel Stefanescu, Marion Lautenschlager, Michael Bauer, Daisy Zamora, Mark Horowitz, John M. Davis, Stefan Leucht
Summary: This study aimed to investigate whether switching to an antipsychotic with a different receptor binding profile is effective in patients with schizophrenia who did not improve after 2 weeks of treatment. The results showed that switching the non-improvers to a different antipsychotic increased remission rates and was safe. However, there were no significant differences in most secondary efficacy outcomes.
SCHIZOPHRENIA BULLETIN
(2022)
Article
Neurosciences
Young Sup Woo, Sung-Yong Park, Bo-Hyun Yoon, Won-Seok Choi, Sheng-Min Wang, Won-Myong Bahk
Summary: This study compared the efficacy and tolerability of continued olanzapine (OLA) versus amisulpride (AMI) augmentation in schizophrenic patients with poor response to OLA monotherapy. The results showed significant differences in PANSS total score and PANSS-positive subscale score between the OLA and AMI groups. However, there were no statistically significant differences between the two groups in PANSS-negative subscale, PANSS-general subscale, Brief Psychiatric Rating Scale, and Clinical Global Impression-Severity (CGI-S) scale scores.
CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE
(2022)
Article
Neurosciences
Cuifang Zhu, Ruofan Li, Mingliang Ju, Xudong Xiao, Ti-Fei Yuan, Zhixing Jin, Jing Zhao
Summary: Metformin has shown efficacy and safety in the treatment of amisulpride-induced hyperprolactinemia. After eight weeks of intervention, the metformin group had a significant decrease in serum prolactin levels, while the placebo group showed a slight increase. There was a significant difference in prolactin changes between the two groups, but no significant difference in the incidence of adverse drug reactions.
FRONTIERS IN MOLECULAR NEUROSCIENCE
(2022)
Review
Neurosciences
Calogero Crapanzano, Ilaria Casolaro, Stefano Damiani, Chiara Amendola
Summary: Anxiety symptoms and disorders are common in patients with schizophrenia and are associated with greater severity of symptoms, cognitive impairment, poorer functioning and quality of life. Atypical antipsychotics may play a role in treating comorbid anxiety symptoms.
CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE
(2022)
Article
Chemistry, Medicinal
Mengyue Fu, Shi Chen, Rui Xu, Jie Chen, Xuehan Chen, Wanxia Gan, He Huang, Guangyou Duan
Summary: This study aimed to explore the effects of intravenous analgesia using tramadol on postoperative depression, anxiety, and sleep in women undergoing abdominal endoscopic surgery. The results showed that intravenous analgesia with tramadol can effectively improve postoperative depression and sleep, with no impact on anxiety state.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2022)
Article
Pharmacology & Pharmacy
Eirik Kjelby, Rolf Gjestad, Farivar Fathian, Igne Sinkeviciute, Renata Alisauskiene, Liss Anda, Else-Marie Loberg, Solveig Klaebo Reitan, Inge Joa, Tor Ketil Larsen, Maria Rettenbacher, Jan Oystein Berle, Ole Bernt Fasmer, Rune Andreas Kroken, Erik Johnsen
Summary: In a 12-month randomized clinical trial, amisulpride, aripiprazole, and olanzapine were found to have similar effectiveness in treating depressive symptoms in patients with schizophrenia.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
(2023)
Article
Health Care Sciences & Services
Dror Ben-Zeev, Ayesha Chander, Justin Tauscher, Benjamin Buck, Subigya Nepal, Andrew Campbell, Guy Doron
Summary: This study conducted a fully remote randomized waitlist-controlled trial of CORE, a smartphone intervention for people with serious mental illness (SMI). Results showed that CORE was highly usable and acceptable, with significant reductions in psychiatric symptoms and disability levels, as well as improvements in recovery and self-esteem.
JOURNAL OF MEDICAL INTERNET RESEARCH
(2021)
Article
Psychiatry
Ramajayam Govindaraj, Shalini S. Naik, Urvakhsh M. Mehta, Manjunath Sharma, Shivarama Varambally, B. N. Gangadhar
Summary: The study demonstrated that 6 weeks of add-on yoga therapy could improve social cognition in individuals with schizophrenia compared to a waitlist control group. However, the change in social cognition was not correlated with changes in putative Mirror Neuron System (MNS) activity. Further research is needed to investigate the mechanisms of yoga and replicate the findings in a larger sample.
ASIAN JOURNAL OF PSYCHIATRY
(2021)
Article
Psychiatry
Renata Alisauskiene, Erik Johnsen, Rolf Gjestad, Rune A. Kroken, Eirik Kjelby, Igne Sinkeviciute, Farivar Fathian, Inge Joa, Solveig Klaebo Reitan, Maria Rettenbacher, Else-Marie Loberg
Summary: This study investigated the influence of drug use on the effectiveness of antipsychotic medication in patients with schizophrenia spectrum disorders (SSD). The results showed no significant differences in effectiveness among the three studied antipsychotics, regardless of drug use. However, older patients in the drug use group showed greater reduction in PANSS positive subscale score during treatment with amisulpride. Therefore, amisulpride may be a suitable choice for older patients with drug use.
GENERAL HOSPITAL PSYCHIATRY
(2023)
Article
Psychology, Clinical
J. Weijers, C. Ten Kate, W. Viechtbauer, L. J. A. Rampaart, E. H. M. Eurelings, J. P. Selten
Summary: The study suggests that adding mentalization-based treatment for non-affective psychotic disorder (NAPD) may lead to more robust improvements in social functioning compared to treatment as usual (TAU), especially for patients with recent onset of psychosis.
PSYCHOLOGICAL MEDICINE
(2021)
Article
Psychiatry
L. A. Stabell, E. Johnsen, R. A. Kroken, E. M. Loberg, A. Blindheim, I. Joa, S. K. Reitan, M. Rettenbacher, P. Munk-Jorgensen, R. Gjestad
Summary: This study investigates the impact of antipsychotic treatment on clinical insight. It finds that antipsychotics, such as amisulpride and olanzapine, can improve insight over and above the reduction in total psychosis symptoms. However, the effect on insight compared to the effect of symptom reduction is still uncertain.
Article
Psychiatry
Iris E. Sommer, Shiral S. Gangadin, Lot D. de Witte, Sanne Koops, C. van Baal, Sabine Bahn, Hemmo Drexhage, N. E. M. van Haren, Wim Veling, R. Bruggeman, Peter Martens, Sybren Wiersma, Selene R. T. Veerman, Koen P. Grootens, Nico van Beveren, Rene S. Kahn, Marieke J. H. Begemann
Summary: This study found that augmentation with simvastatin did not significantly affect total symptom severity in early SSD patients after 12 months of treatment, but did show lower symptom severity in the simvastatin group at 6 and 24 months. There was no main treatment effect on cognition and secondary outcomes. Adverse events occurred more frequently in the placebo group compared to the simvastatin group.
SCHIZOPHRENIA BULLETIN
(2021)
Letter
Pharmacology & Pharmacy
Buddhadev Panja, S. Bhowmick, V. R. Chowrasia, Shipra Bhattacharya, R. N. Chatterjee, Arindam Sen, Manjula Sarkar, A. K. Ram, P. K. Mukherjee
INDIAN JOURNAL OF PHARMACOLOGY
(2015)
Letter
Orthopedics
Chin T. Lim, Stuart B. Goodman, James I. Huddleston, Alex H. S. Harris, Subhrojyoti Bhowmick, William J. Maloney, Derek F. Amanatullah
JOURNAL OF ARTHROPLASTY
(2017)
Article
Orthopedics
Chin Tat Lim, Stuart B. Goodman, James I. Huddleston, Alex H. S. Harris, Subhrojyoti Bhowmick, William J. Maloney, Derek F. Amanatullah
JOURNAL OF ARTHROPLASTY
(2017)
Article
Orthopedics
Chin Tat Lim, Stuart B. Goodman, James I. Huddleston, Alex H. S. Harris, Subhrojyoti Bhowmick, William J. Maloney, Derek F. Amanatullah
Review
Orthopedics
Michael J. Chen, Subhrojyoti Bhowmick, Lucille Beseler, Kristin L. Schneider, Scott I. Kahan, John M. Morton, Stuart B. Goodman, Derek F. Amanatullah
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME
(2018)
Review
Pharmacology & Pharmacy
Saibal Das, Subhrojyoti Bhowmick, Sayali Tiwari, Sukanta Sen
CLINICAL DRUG INVESTIGATION
(2020)
Review
Public, Environmental & Occupational Health
Subhrojyoti Bhowmick, Amit Dang, B. N. Vallish, Sumit Dang
Summary: This review examined the safety and efficacy of Ivermectin (IVM) and doxycycline (DOXY) as monotherapy and combination therapy in COVID-19 management. The evidence on the efficacy of IVM, DOXY, or their combination in COVID-19 management is not strong enough to draw definitive conclusions.
Article
Pharmacology & Pharmacy
Subhrojyoti Bhowmick, Ashok K. Shenoy
JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS
(2018)